![Raj Airey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Raj Airey
Directeur/Membre du Conseil chez Cytovation AS
Profil
Raj Airey is currently a Director at Cytovation AS.
Previously, he worked as a Director & Chief Strategy Officer at SOM Innovation Biotech SA. He completed his undergraduate degree at the University of London.
Postes actifs de Raj Airey
Sociétés | Poste | Début |
---|---|---|
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Directeur/Membre du Conseil | - |
Anciens postes connus de Raj Airey
Sociétés | Poste | Fin |
---|---|---|
SOM Innovation Biotech SA
![]() SOM Innovation Biotech SA Pharmaceuticals: MajorHealth Technology SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | - |
Formation de Raj Airey
University of London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
SOM Innovation Biotech SA
![]() SOM Innovation Biotech SA Pharmaceuticals: MajorHealth Technology SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain. | Health Technology |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Commercial Services |